Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. (Q38375504)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

main subject

phase I clinical trial

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

Swiss Group for Clinical Cancer Research

12 March 2020

object named as

Swiss Group for Clinical Cancer Research (SAKK)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

D Hess

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

R von Moos

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

K Homicsko

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

M Joerger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

M Mark

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

C J Ackermann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

S Allegrini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

C V Catapano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

A Xyrafas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

M Enoiu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

S Berardi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

P Gargiulo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

C Sessa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

20 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

766-772

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28317088%20AND%20SRC:MED&resulttype=core&format=json

Hedgehog signalling in cancer formation and maintenance

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

The hedgehog signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

The utility of hedgehog signaling pathway inhibition for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Role of weekly paclitaxel in the treatment of advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Smoothened antagonists reverse taxane resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-017-0454-Z

Hedgehog beyond medulloblastoma and basal cell carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28317088

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28317088

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Targeting the Hedgehog pathway in cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28317088